Neulastim Dosage/Direction for Use

Neulastim therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.
Posology: Adults (≥ 18 years): One 6 mg dose (a single pre-filled syringe) of Neulastim is recommended for each chemotherapy cycle, administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy.
Paediatric population: The safety and efficacy of Neulastim in children have not yet been established. Currently available data are described in Adverse Reactions, Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions but no recommendation on a posology can be made.
Patients with renal impairment: No dose change is recommended in patients with renal impairment, including those with end stage renal disease.
Method of administration: Neulastim is injected subcutaneously. The injections should be given into the thigh, abdomen or upper arm. For instructions on handling of the medicinal product before administration, see Special precautions for disposal and other handling under Cautions for Usage.